To conduct clinical development of a compound for the treatment of covid-19.

Active Definitive Contract Awarded Last action

Contract number
75N93023C00052
Awardee
Awarding agency
Obligated
$11,286,393

Award facts

Opportunity
  • HHSNIHNIAIDBAA202301 Solicitation number
Contract value 100% obligated
$11,286,393.00 Current and potential, with all options
Completion date 95% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 7 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
South San Francisco, CA 94080, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00004 $0
Funding Only Action P00003 $1,516,140
Other Administrative Action P00002 $0
Change Order P00001 $1,300,776
Original award $8,469,477

About this award

This is a $11,286,393.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Aligos Therapeutics Inc. to conduct clinical development of a compound for the treatment of COVID-19. The contract has an ultimate completion date of December 31, 2026 and does not have a set-aside designation. The award supports NIAID's efforts to develop COVID-19 treatments.

Quick answers

Who was awarded contract 75N93023C00052?

75N93023C00052 was awarded to Aligos Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 22, 2023.

How much is contract 75N93023C00052 worth?

The government has obligated $11,286,393 on 75N93023C00052.

Was contract 75N93023C00052 competed?

The extent of competition for 75N93023C00052 was full and open competition. The government received 7 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award